Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

354 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Dysgeusia in patients with advanced urothelial carcinoma receiving enfortumab vedotin, platinum-based chemotherapy, or immune check point inhibitors: time-course assessment using chemotherapy-induced taste alteration scale.
Miyake M, Nishimura N, Oda Y, Miyamoto T, Tomizawa M, Shimizu T, Hori S, Morizawa Y, Gotoh D, Nakai Y, Torimoto K, Fujii T, Tanaka N, Fujimoto K. Miyake M, et al. Among authors: tomizawa m. J Chemother. 2024 Apr 17:1-13. doi: 10.1080/1120009X.2024.2340885. Online ahead of print. J Chemother. 2024. PMID: 38628149
Enfortumab vedotin following platinum-based chemotherapy and immune checkpoint inhibitors for advanced urothelial carcinoma: response, survival and safety analysis from a multicentre real-world Japanese cohort.
Miyake M, Nishimura N, Oda Y, Miyamoto T, Ohmori C, Takamatsu N, Itami Y, Tachibana A, Matsumoto Y, Kiba K, Tomioka A, Yamamoto H, Okajima E, Masaomi K, Sakamoto K, Tomizawa M, Shimizu T, Ohnishi K, Hori S, Morizawa Y, Gotoh D, Nakai Y, Torimoto K, Tanaka N, Fujimoto K; Nara Urological Research and Treatment Group. Miyake M, et al. Among authors: tomizawa m. Jpn J Clin Oncol. 2024 Mar 9;54(3):329-338. doi: 10.1093/jjco/hyad170. Jpn J Clin Oncol. 2024. PMID: 38061911
Response to Pembrolizumab After Dose-Reduced Cisplatin Plus Gemcitabine Chemotherapy Is Inferior to That After Carboplatin Plus Gemcitabine Chemotherapy in Cisplatin-Unfit Patients With Advanced Urothelial Carcinoma.
Miyake M, Shimizu T, Nishimura N, Kiba K, Maesaka F, Oda Y, Tachibana A, Tomizawa M, Ohmori C, Matsumura Y, Ichikawa K, Mizobuchi S, Yoshikawa T, Hori S, Morizawa Y, Gotoh D, Nakai Y, Anai S, Torimoto K, Aoki K, Tanaka N, Fujimoto K; Nara Urological Research and Treatment Group. Miyake M, et al. Among authors: tomizawa m. Clin Genitourin Cancer. 2022 Apr;20(2):196.e1-196.e9. doi: 10.1016/j.clgc.2021.11.006. Epub 2021 Nov 15. Clin Genitourin Cancer. 2022. PMID: 34916166
Organ-Specific and Mixed Responses to Pembrolizumab in Patients with Unresectable or Metastatic Urothelial Carcinoma: A Multicenter Retrospective Study.
Shimizu T, Miyake M, Nishimura N, Inoue K, Fujii K, Iemura Y, Ichikawa K, Omori C, Tomizawa M, Maesaka F, Oda Y, Miyamoto T, Sakamoto K, Kiba K, Tanaka M, Oyama N, Okajima E, Fujimoto K, Hori S, Morizawa Y, Gotoh D, Nakai Y, Torimoto K, Tanaka N, Fujimoto K. Shimizu T, et al. Among authors: tomizawa m. Cancers (Basel). 2022 Mar 29;14(7):1735. doi: 10.3390/cancers14071735. Cancers (Basel). 2022. PMID: 35406508 Free PMC article.
The Japanese health care system-based cost-effectiveness of photodynamic diagnosis-assisted transurethral resection of bladder tumor for non-muscle invasive bladder cancer.
Nishimura N, Miyake M, Miyamoto T, Tomizawa M, Shimizu T, Morizawa Y, Hori S, Gotoh D, Nakai Y, Torimoto K, Tanaka N, Fujimoto K. Nishimura N, et al. Among authors: tomizawa m. Jpn J Clin Oncol. 2023 Mar 30;53(4):343-348. doi: 10.1093/jjco/hyac203. Jpn J Clin Oncol. 2023. PMID: 36585780
Clinical impact of the intensity of follow-up cystoscopy in patients with high-risk non-muscle-invasive bladder cancer.
Miyake M, Nishimura N, Nishioka Y, Fujii T, Oda Y, Miyamoto T, Tomizawa M, Shimizu T, Owari T, Ohnishi K, Hori S, Morizawa Y, Gotoh D, Nakai Y, Torimoto K, Tanaka N, Imamura T, Fujimoto K. Miyake M, et al. Among authors: tomizawa m. Int Urol Nephrol. 2024 Mar;56(3):827-837. doi: 10.1007/s11255-023-03851-3. Epub 2023 Nov 1. Int Urol Nephrol. 2024. PMID: 37910382
354 results